Concepedia

Philip W. Howard

PW

12

Publications

586

Citations

11

H-Index

2009

Active since

Affiliations

Spirogen (United Kingdom)(Current)

University College London

University of Cambridge

Philip W. Howard is an author at Spirogen (United Kingdom) specializing in drug discovery, medicinal chemistry, and medicine.

Top concepts

Drug DiscoveryMedicinePharmacologyMedicinal ChemistryNatural SciencesBiomolecular EngineeringImmunologyBiochemistryAntibody EngineeringEngineering

Publications per year

2009–2020

12

Publications

12

A Potent Anti-CD70 Antibody–Drug Conjugate Combining a Dimeric Pyrrolobenzodiazepine Drug with Site-Specific Conjugation Technology

Scott C. Jeffrey, Patrick Burke, Robert P. Lyon et al. · Bioconjugate Chemistry · 2013 · 241 citations

Drug Target, Immunology, Molecular Biology +21

Discovery of Peptidomimetic Antibody–Drug Conjugate Linkers with Enhanced Protease Specificity

BinQing Wei, Janet Gunzner-Toste, Hui Yao et al. · Journal of Medicinal Chemistry · 2017 · 104 citations

Peptide Engineering, Immunology, Peptide Science +17

Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody–Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer

Song Cho, Francesca Zammarchi, David G. Williams et al. · Molecular Cancer Therapeutics · 2018 · 46 citations

Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody–Drug Conjugate Targeting 5T4

Jay Harper, Christopher Lloyd, Nazzareno Dimasi et al. · Molecular Cancer Therapeutics · 2017 · 45 citations · Full text

Integrin αvβ6-specific therapy for pancreatic cancer developed from foot-and-mouth-disease virus

Kate M. Moore, Ami V. Desai, Beatriz de Luxán‐Delgado et al. · Theranostics · 2020 · 42 citations · Full text

Rows per page

1–5 of 12